ArticleTherapeutic advances in medical oncology2025

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).

Mazyar Shadman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.